Bristol-Myers Squibb (BMS) has appointed one of the world’s leading oncologists to its board of directors.
Dr Thomas Lynch, who is currently director of the Yale Cancer Center, will join the pharma company’s science and technology committee.
In addition to his role at Yale, Dr Lynch is also physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven in the US, as well as professor of medical oncology at the same hospital.
Lamberto Andreotti, CEO of BMS, praised both Dr Lynch’s work in cancer as well as his business leadership.
“As we advance our work in immuno-oncology and build our leadership position in oncology, his guidance and scientific and business perspectives will be invaluable,” said Andreotti.
Prior to his current roles at Yale, Dr Lynch was a professor of medicine at Harvard Medical School and chief of haematology and oncology at Massachusetts General Hospital (MGH) Cancer Center.
He also served as director of the Center for Thoracic Cancers at MGH and director of medical oncology at MGH Thoracic Oncology Center.